Health-care companies fell as traders hedged their bets on the outlook for growth in the sector. Insurers, including Elevance, which recently warned of cost pressures from its Affordable Care Act ...

Arbitrators cleared the way for the long-delayed $53 billion acquisition after Exxon tried to pre-empt the deal. 3M raised its full-year earnings outlook after beating expectations in the second ...

The U.S. Food and Drug Administration's panel of independent advisers on Friday voted against the efficacy of Otsuka Pharma's ...

GSK was trying to revive a product pulled from US markets in 2022. Its shares fell 4.6 per cent, or 65p, to 1348p.

A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector.

The analyst further reasoned that the high ocular toxicity rates, including keratopathy and visual acuity changes, are ...

The FDA oncologic drugs advisory committee voted against the approval of GSK’s blood cancer treatment Blenrep, delivering a setback to the drugmaker’s efforts to reintroduce the drug to the U.S.

The FDA has declined to approve Columvi, in combination with the chemo regimen GemOx, for the treatment of second-line DLBCL patients who are not eligible for autologous stem cell transplant, Roche ...

The anemia treatment missed its main goal in a myelofibrosis study. Meanwhile, Blenrep's return to the U.S. market may have ...

In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...

The FDA’s Oncologic Drugs Advisory Committee has voted against the benefit/risk profile of GSK’s Blenrep just days before the drug’s PDUFA date.